Hans A. Schlößer

TL;DR: This review provides a comprehensive overview of the mechanisms underlying CRS pathophysiology, risk factors, clinical presentation, differential diagnoses, and prognostic factors and gives practical guidance to the management of the cytokine release syndrome.

TL;DR: Combining VEGF and PD-L1 blockade could be of therapeutic benefit to patients with small cell lung cancer, and the data strongly suggest that a combination of anti-VEGF and anti-PD- L1 therapies can be an effective treatment strategy in patients with SCLC.

TL;DR: The B-cell infiltrate of primary CRC is characterized by an accumulation of terminally differentiated memory B cells or plasma cells suggestive of a specific immune response against the tumor, however advanced tumors and metastases are also infiltrated by a considerable number of regulatory B cells.

TL;DR: The tumor microenvironment of HNSCC is characterized by a strong infiltration of regulatory T cells and high checkpoint molecule expression on T-cell subsets, which is of high translational relevance.

TL;DR: Different immune infiltration patterns in relation to serological TAA response detection and the presence of B cell subpopulations in HNSCC that can engage in tumor promoting and antitumor activity are demonstrated.